Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial - PubMed (original) (raw)
Clinical Trial
. 1998 Nov;89(5):699-706.
doi: 10.3171/jns.1998.89.5.0699.
M J Shepard, T R Holford, L Leo-Summers, E F Aldrich, M Fazl, M G Fehlings, D L Herr, P W Hitchon, L F Marshall, R P Nockels, V Pascale, P L Perot Jr, J Piepmeier, V K Sonntag, F Wagner, J E Wilberger, H R Winn, W Young
Affiliations
- PMID: 9817404
- DOI: 10.3171/jns.1998.89.5.0699
Clinical Trial
Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial
M B Bracken et al. J Neurosurg. 1998 Nov.
Abstract
Object: A randomized double-blind clinical trial was conducted to compare neurological and functional recovery and morbidity and mortality rates 1 year after acute spinal cord injury in patients who had received a standard 24-hour methylprednisolone regimen (24MP) with those in whom an identical MP regimen had been delivered for 48 hours (48MP) or those who had received a 48-hour tirilazad mesylate (48TM) regimen.
Methods: Patients for whom treatment was initiated within 3 hours of injury showed equal neurological and functional recovery in all three treatment groups. Patients for whom treatment was delayed more than 3 hours experienced diminished motor function recovery in the 24MP group, but those in the 48MP group showed greater 1-year motor recovery (recovery scores of 13.7 and 19, respectively, p=0.053). A greater percentage of patients improving three or more neurological grades was also observed in the 48MP group (p=0.073). In general, patients treated with 48TM recovered equally when compared with those who received 24MP treatments. A corresponding recovery in self care and sphincter control was seen but was not statistically significant. Mortality and morbidity rates at 1 year were similar in all groups.
Conclusions: For patients in whom MP therapy is initiated within 3 hours of injury, 24-hour maintenance is appropriate. Patients starting therapy 3 to 8 hours after injury should be maintained on the regimen for 48 hours unless there are complicating medical factors.
Similar articles
- Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Bracken MB, et al. JAMA. 1997 May 28;277(20):1597-604. JAMA. 1997. PMID: 9168289 Clinical Trial. - A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J, et al. Bracken MB, et al. N Engl J Med. 1990 May 17;322(20):1405-11. doi: 10.1056/NEJM199005173222001. N Engl J Med. 1990. PMID: 2278545 Clinical Trial. - Steroids for acute spinal cord injury.
Bracken MB. Bracken MB. Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD001046. doi: 10.1002/14651858.CD001046.pub2. Cochrane Database Syst Rev. 2012. PMID: 22258943 Free PMC article. Review. - [Methylprednisolone in the treatment of acute spinal cord injury has become more and more questioned].
Kronvall E, Sayer FT, Nilsson OG. Kronvall E, et al. Lakartidningen. 2005 Jun 13-26;102(24-25):1887-8, 1890. Lakartidningen. 2005. PMID: 16044768 Review. Swedish.
Cited by
- Advances and Challenges in Spinal Cord Injury Treatments.
Alvi MA, Pedro KM, Quddusi AI, Fehlings MG. Alvi MA, et al. J Clin Med. 2024 Jul 13;13(14):4101. doi: 10.3390/jcm13144101. J Clin Med. 2024. PMID: 39064141 Free PMC article. Review. - Targeted-delivery of nanomedicine-enabled methylprednisolone to injured spinal cord promotes neuroprotection and functional recovery after acute spinal cord injury in rats.
Zhao W, Jia Z, Bauman WA, Qin Y, Peng Y, Chen Z, Cardozo CP, Wang D, Qin W. Zhao W, et al. Nanomedicine. 2024 Aug;60:102761. doi: 10.1016/j.nano.2024.102761. Epub 2024 Jun 11. Nanomedicine. 2024. PMID: 38871068 - Advancements in neuroregenerative and neuroprotective therapies for traumatic spinal cord injury.
Fischer G, Bättig L, Stienen MN, Curt A, Fehlings MG, Hejrati N. Fischer G, et al. Front Neurosci. 2024 May 15;18:1372920. doi: 10.3389/fnins.2024.1372920. eCollection 2024. Front Neurosci. 2024. PMID: 38812974 Free PMC article. Review. - Glutathione effect on functional and histological recovery after spinal cord injury in rats.
de Araujo FF, Marcon RM, Cristante AF, Filho TEPB. de Araujo FF, et al. Clinics (Sao Paulo). 2024 Apr 23;79:100359. doi: 10.1016/j.clinsp.2024.100359. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 38657346 Free PMC article. - An updated systematic review of neuroprotective agents in the treatment of spinal cord injury.
Serag I, Abouzid M, Elmoghazy A, Sarhan K, Alsaad SA, Mohamed RG. Serag I, et al. Neurosurg Rev. 2024 Mar 28;47(1):132. doi: 10.1007/s10143-024-02372-6. Neurosurg Rev. 2024. PMID: 38546884 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical